Fig. 1

Flow chart that summarizes the subgroup allocation of all dogs (n = 231) included in the study. The three different parts of the study are indicated by the grey shaded areas: (I) evaluation of serum gastrin concentrations and antisecretory therapy in dogs with CE at the time of enrolment (Ia) and at serial evaluations (Ib); (II) evaluation of serum gastrin concentrations and histopathologic findings in dogs with CE; and (III) estimation of the biological variation of serum gastrin concentrations in dogs with CE